Naveruclif (Paclitaxel)

Paclitaxel is used in the management of solid tumours and certain malignancies, targeting rapidly dividing cancer cells.

• Breast cancer: administered in adjuvant or metastatic settings to inhibit tumour growth.
• Non‑small cell lung cancer: used as first‑line or subsequent therapy for advanced disease.
• Ovarian cancer: given in combination regimens to improve response rates in recurrent disease.
• AIDS‑related Kaposi sarcoma: employed to control lesion progression in immunocompromised patients.

• Paclitaxel binds to the β‑tubulin subunit of microtubules, stabilizing them and preventing depolymerisation. This inhibition of microtubule dynamics blocks the mitotic spindle formation, arresting cells in the G2/M phase of the cell cycle and ultimately leading to apoptosis of rapidly dividing cancer cells.

Paclitaxel may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: hair loss that may be temporary.
• Peripheral neuropathy: tingling or numbness in extremities.
• Nausea and vomiting: gastrointestinal upset common during infusion.
• Fatigue: generalized tiredness during treatment.
• Myalgia: muscle aches and pains.

Serious or Rare Side Effects

• Hypersensitivity reactions: severe allergic responses requiring emergency care.
• Cardiac arrhythmias: irregular heart rhythms observed during infusion.
• Pulmonary toxicity: rare lung inflammation that can impair breathing.
• Severe neutropenia with fever: life‑threatening infection risk.
• Thromboembolic events: blood clots in veins or arteries.

Prior to initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

• Monitor blood counts: perform regular CBC to detect neutropenia.
• Assess for hypersensitivity: pre‑medicate with steroids and antihistamines as recommended.
• Evaluate cardiac function: monitor ECG in patients with known heart disease.
• Adjust for hepatic impairment: consider dose modification in severe liver dysfunction.
• Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paclitaxel interacts with several drug classes that can alter its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase paclitaxel exposure and toxicity.
• Concurrent use with other myelosuppressive agents: can exacerbate bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin): may reduce plasma concentrations, lowering effectiveness.
• Neurotoxic drugs (e.g., vincristine): additive peripheral neuropathy risk.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters as paclitaxel may affect platelet function.